Clinical Trials
37 trialsPlatinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
NeoHTerMa
Semmelweis University
NeoTOP
Sun Yat-sen University
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NRG Oncology
NeoTRACT
University of Kansas Medical Center
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
TELESCOPE
MedSIR
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
PETRA
AstraZeneca
Triple-B
The Netherlands Cancer Institute
PANSY
Fudan University
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital
'ADVANCE' (A Pilot Trial)
Dana-Farber Cancer Institute
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
University of California, Irvine
TCTN
Shanghai Jiao Tong University School of Medicine
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Fox Chase Cancer Center
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting
Oslo University Hospital
PHERGain
MedSIR
CADENCE
Baylor Breast Care Center
CA225200
US Oncology Research
SAFIR02_Breast
UNICANCER
SYNERGY
Jules Bordet Institute
TRAIN-2
The Netherlands Cancer Institute
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Rutgers, The State University of New Jersey
neo-TN
The Netherlands Cancer Institute
Oligo
The Netherlands Cancer Institute